At Mablink Bioscience we develop 3rd generation Antibody-Drug Conjugates (ADC) featuring our proprietary PSARlink technology. We pave the way to a new generation of highly hydrophilic, better tolerated, highly-loaded ADCs with an improved therapeutic index. Read more

Meet our board of directors. Read more

Our strategy is backed by internationally renowned experts in the field of immuno-oncology. Read more

Meet all the organizations who believe in our project. Read more